The streak is alive: management narrates back-to-back quarters of the same improvement and shows this quarter extended i
The model's full reasoning — Q1 2018 call → NOWe need answer YES/NO. Need analyze transcript. Need determine if management presents just-reported period as latest step in unbroken still-running sequence of quarter-after-quarter improvement in same part of business, explicitly connecting this period to immediately preceding period(s) as one continuing climb, with real current-period evidence. Need be strict. Let's parse transcript. Management remarks: Larry, Dave. They discuss Q1 2018 results. They mention "solid performance in the first quarter in line with expectations." They discuss Aetna, integration, innovations. Financial highlights: adjusted EPS $1.48 increase 26.5% over LY. Revenue increased 2.6%. Operating profit increased 3.4%. They discuss PBM, Retail/LTC. They mention "Our first quarter results underscored the early success we are achieving in our four-point plan to return to healthy growth. Our partnerships are driving script growth, while our streamlining effort is improving enterprise-wide efficiencies." That is not necessarily quarter-over-quarter streak. They mention "we are continuing to make significant progress in enterprise streamlining efforts" and "we are already benefiting from enhancements." But no explicit "another quarter of growth" or "fourth consecutive quarter" etc. They compare to prior year mostly. They mention "we have seen a nearly 70% reduction in Caremark's rejects and have eliminated more than 8 million rejections in the first quarter alone." That's not a streak. Need look for any sequential quarter-to-quarter chaining. Dave: "Operating profit for the total enterprise grew 3.4% in the quarter, while operating margins remained relatively flat year-over-year at 4.5%." No sequential. "Net interest expense in the quarter decreased approximately $10 million from LY to $242 million, but is consistent with the fourth quarter of 2017." That's not improvement. "We have seen an uptick by a number of both Optum and Cigna clients..." "Our initiatives are driving growth of adjusted scripts to spend; and as a result, our market shares increased by nearly 140 basis points in the quarter to 24.6%." That's year-over-year? "Same store sales were slightly above expectations at 5.8%, with adjusted same-store script growth of 8.5% at the high end of our guidance range." No sequential.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| CRGO | Freightos Limited | Q1 2024 | 2024-05-20 | C+ |
| WRBY | Warby Parker Inc. | Q1 2024 | 2024-05-09 | A |
| MNKD | MannKind Corporation | Q4 2023 | 2024-02-27 | C |
| DXCM | DexCom, Inc. | Q4 2023 | 2024-02-08 | B+ |
| MFC | Manulife Financial Corporation | Q3 2023 | 2023-11-09 | C+ |
| BMBL | Bumble Inc. | Q3 2023 | 2023-11-07 | F |
| GOLD | Barrick Gold Corporation | Q3 2023 | 2023-11-02 | C |
| ALL | The Allstate Corporation | Q3 2023 | 2023-11-02 | C+ |
| GRBK | Green Brick Partners, Inc. | Q3 2023 | 2023-11-01 | B |
| TEL | TE Connectivity Ltd. | Q4 2023 | 2023-11-01 | B |
| PTN | Palatin Technologies, Inc. | Q4 2023 | 2023-09-29 | D |
| AEIS | Advanced Energy Industries, Inc. | Q2 2023 | 2023-08-03 | B |
| PFIE | Profire Energy, Inc. | Q1 2023 | 2023-05-13 | B |
| SPIR | Spire Global, Inc. | Q1 2023 | 2023-05-10 | B |
| TSN | Tyson Foods, Inc. | Q2 2023 | 2023-05-08 | D |
| CALX | Calix, Inc. | Q1 2023 | 2023-04-20 | C+ |
| TGT | Target Corporation | Q4 2022 | 2023-02-28 | C |
| VRE | Veris Residential, Inc. | Q4 2022 | 2023-02-22 | D |
| TOST | Toast, Inc. | Q4 2022 | 2023-02-16 | C+ |
| PI | Impinj, Inc. | Q4 2022 | 2023-02-08 | B+ |
| PKOH | Park-Ohio Holdings Corp. | Q3 2022 | 2022-11-13 | B |
| SIBN | SI-BONE, Inc. | Q3 2022 | 2022-11-07 | C+ |
| KFY | Korn Ferry | Q4 2022 | 2022-06-22 | B |
| WRB | W. R. Berkley Corporation | Q1 2022 | 2022-04-26 | B |
| HROW | Harrow Health, Inc. | Q4 2021 | 2022-03-10 | C |
| ALHC | Alignment Healthcare, Inc. | Q3 2021 | 2021-11-06 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| PRPO | Precipio, Inc. | Q3 2018 | 2018-11-19 | D |
| ALB | Albemarle Corporation | Q3 2018 | 2018-11-08 | B |
| FMS | Fresenius Medical Care AG & Co. KGaA | Q2 2018 | 2018-07-31 | C |
| ORAN | Orange SA | Q2 2018 | 2018-07-26 | B |
| NOVT | Novanta Inc. | Q4 2017 | 2018-05-12 | B+ |
| EPC | Edgewell Personal Care Company | Q3 2017 | 2017-08-08 | D |
| CNS | Cohen & Steers, Inc. | Q2 2017 | 2017-07-20 | B |
| FNV | Franco-Nevada Corporation | Q3 2016 | 2016-11-08 | B+ |
| GES | Guess?, Inc. | Q1 2017 | 2016-05-25 | F |
| SAN | Banco Santander, S.A. | Q4 2015 | 2016-01-27 | B |
MNKD · Q4 2023 → YESThe question is: Does management present the just-reported period as THE LATEST STEP IN AN UNBROKEN, STILL-RUNNING SEQUENCE OF QUARTER-AFTER-QUARTER IMPROVEMENT IN THE SAME PART OF THE BUSINESS — expl...YES The transcript explicitly frames the just-reported quarter as the second consecutive (or second successive) profitable quarter for the endocrine business unit and for the Company overall. Management ties this directly to actual results in the current period (net income of $1 million GAAP and $7 million non-GAAP in Q4) following the prior 2023 quarter, and states they will continue to focus on growing the profitability of the endocrine business unit, which has had a positive contribution for two straight quarters.
CYBR · Q3 2021 → YESThe question is: Does management present the just-reported period as THE LATEST STEP IN AN UNBROKEN, STILL-RUNNING SEQUENCE OF QUARTER-AFTER-QUARTER IMPROVEMENT IN THE SAME PART OF THE BUSINESS — expl...YES Udi Mokady explicitly frames Q3 as “another amazing quarter” that follows “an incredible second quarter,” using the single word “acceleration” to describe the quarter. He then quantifies the extension with concrete current-period metrics: subscription ARR growth accelerated to 131 % (reaching $139 million), total 38 % ARR growth (reaching $344 million), recurring revenue growth accelerated to 41 % ($89 million), and new logos accelerated to over 230.
MFC · Q3 2023 → YESThe question is: Does management present the just-reported period as THE LATEST STEP IN AN UNBROKEN, STILL-RUNNING SEQUENCE OF QUARTER-AFTER-QUARTER IMPROVEMENT IN THE SAME PART OF THE BUSINESS — expl...YES Roy Gori explicitly frames core ROE as having been ahead of the 15%+ medium-term target for the second consecutive quarter, while noting a 35% rise in core EPS this quarter (on top of steady year-on-year growth in core earnings over the past three quarters). Colin reinforces the sequential nature by stating that core ROE “increase[d] to 16.8%” this quarter.